Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 4Classical hematology 3Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 76Anemia, Refractory, with Excess of Blasts 72Myelodysplastic Syndromes 69Leukemia 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Anemia 50Leukemia, Lymphocytic, Chronic, B-Cell 44Leukemia, Myelomonocytic, Chronic 42Lymphoma, Non-Hodgkin 41Multiple Myeloma 39Hodgkin Disease 36Myeloproliferative Disorders 34Primary Myelofibrosis 33Thrombocytopenia 32Leukemia, Myelogenous, Chronic, BCR-ABL Positive 32Lymphoma 31Neoplasms 29Anemia, Aplastic 29Congenital Abnormalities 27Anemia, Refractory 25Lymphoma, Follicular 23Lymphoma, Mantle-Cell 21Lymphoma, B-Cell, Marginal Zone 18Burkitt Lymphoma 18Lymphoma, Large B-Cell, Diffuse 17Leukemia, Myeloid, Chronic-Phase 17Venous Thromboembolism 16Lymphoma, Large-Cell, Immunoblastic 16Leukemia, Myeloid, Accelerated Phase 16Waldenstrom Macroglobulinemia 14

Interventions

11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2Surveys and Questionnaires 1ON 01910 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Splenomegaly × Classical hematology × Clear all
NCT02055781 2021-11-18

PAC326

CTI BioPharma

Phase 3 Terminated
311 enrolled 12 charts
Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT01773187 2020-09-29

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

CTI BioPharma

Phase 3 Terminated
327 enrolled 11 charts
Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT02730884 2020-08-07

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 6 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Splenomegaly, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡